New made-in-Canada therapy for bladder cancer shows promising results

	Tweet

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

“I am optimistic about the results of the trial,” says Dr. Morales, professor emeritus in the Department of Urology at Queen’s University and director of the Queen’s University Centre for Applied Urological Research. “Positive results in the next phase of trials will move us very close to a far more effective bladder cancer treatment.”

Initial human trials found that Urocidin is effective and much safer than previous treatment options for cases of superficial bladder cancer that is not responsive to Bacillus Calmette-Guérin (BCG) therapy.

A recent large North American clinical trial confirmed the initial findings, with 25 per cent of patients becoming disease-free after one year of therapy with the new drug. Patients also tolerated Urocidin well.

Dr. Morales spearheaded BCG as a bladder cancer treatment in the 1970s in collaboration with the Cancer Research Institute of New York. BCG provoked an immune response strong enough to eliminate some bladder cancers without chemicals. It was also the first effective agent approved by the FDA against solid tumors. BCG remains the first choice to treat superficial bladder cancer due to its superior efficacy over chemotherapy drugs; however, as a live bacterium, it has the potential for serious adverse effects.

“There has been a lot of concern about the adverse effects of BCG,” explains Dr. Morales. “I’ve always thought that we should look for something better. Urocidin could be what we’re looking for.”
Until the discovery of BCG as a bladder cancer therapy, the only alternative short of bladder removal was to put chemicals into the bladder.

Urocidin was developed by Bioniche Life Sciences Inc. A second Phase III clinical trial is underway, funded by Bioniche’s licensing partner, Endo Pharmaceuticals.

###

Queen’s University
Kingston, Ontario, Canada. K7L 3N6. 613.533.2000

RELATED STORIES:
New Trial Targets Kidney Cancer Drug in Bladder Cancer   Radiation does not improve survival for rare, invasive bladder cancer   Less bladder cancer in frequent painkiller users   New treatment option studied for bladder cancer   Cholesterol drug inhibits cancer cells in lab   Survival and Response to Therapy of Non-Invasive Bladder Cancer Patients   Variation in prostate stem cell antigen gene raises bladder cancer risk   Stanford computer algorithm used to identify bladder cancer marker   Blood test may find markers of bladder cancer risk   Extract of broccoli sprouts may protect against bladder cancer   Genetic analysis may predict risk of invasive bladder cancer   Sales jobs tied to bladder cancer risk   Robotic Surgery Extends Benefits to Bladder Cancer Patients   Survivors of Childhood Cancers Treated with Cyclophosphamide More Likely to Develop Bladder Cancer   Arsenic cancer risk still high decades later in Chile region   New Bladder Cancer Therapy for Patients Unresponsive to Standard Treatment   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Bladder Cancer Study Determines Optimal Treatment   Not enough evidence for bladder cancer screening   Bladder cancer: Need for a standardized protocol of management   Consumption of Cultured Milk Products May Reduce Bladder Cancer Risk   Gene test shows which bladder cancer patients may have cancer spread

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]